Mirabegron

• CAS: 223673-61-8
• Catalog Number: ACM223673618
• Category: Other Products
• Molecular Weight: 396.506
• Molecular Formula: C21H24N4O2S
• Description: Mirabegron tablets were developed by Astellas Pharmaceuticals, Inc. and launched in Japan on September 16, 2011, and approved by the U.S. Food and Drug Administration (FDA) on June 28, 2012, for the treatment of overactive bladder (OAB) in adults. Mirabella is the first β3-adrenoceptor agonist drug in the class for the treatment of overactive bladder disorder, and its successful launch fills the gap in the treatment of overactive bladder disorder with β-adrenoceptor agonists.
• Synonyms: N-(4-(2-(2-hydroxy-2-phenylethylamino)ethyl)phenyl)-2-(2-aminothiazol-4-yl)acetamide;YM-178;MIRABEQRON;2-Amino-N-[4-[2-[[(2R)-2-hydroxy-2-phenyl-ethyl]amino]-ethyl]phenyl]-4-thiazoleacetamide;2-(2-amino-1,3-thiazol-4-yl)-N-(4-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}phenyl)acetamide
• Melting Point: 138-140°C
• Density: 1.313
• Appearance: Light yellow to yellow solid
• LogP: 3.81730
• PSA: 128.51
• Storage Conditions: Store in a tightly closed container , in a cool and dry place.
• Vapor Pressure: 5.45E-20mmHg at 25°C